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doi:10.1016/j.jtcvs.2006.04.037bjective: Postoperative mediastinitis after median sternotomy is associated with
isability and mortality. The aim of this study was to identify risk factors for
ortality 1 year after postoperative mediastinitis diagnosis.
ethods: Postoperative mediastinitis was defined as an organ-space infection in-
olving the mediastinum and necessitating debridement. A total of 183 cases of
ostoperative mediastinitis were prospectively identified from infection control
atabases. By using univariate and multivariate analysis, clinical risk factors for
-year mortality were identified.
esults: Of 183 patients, 36 (19.7%) died within 3 months of the initial operation.
verall, 51 (33%) died during the study period (the median time to death from the
ate of diagnosis was 37 days [interquartile range, 11,139 days]). In multivariate
nalysis, independent predictors of 1-year mortality were a greater than 3-day delay
n sternal closure after debridement (hazard ratio, 6.27; P  .001), age greater than
5 years (hazard ratio, 2.29; P  .015), serum creatinine level greater than 2 mg/dL
efore debridement (hazard ratio, 2.52; P  .019), stay in an intensive care unit
efore sternal debridement (hazard ratio, 5.56; P  .001), and postoperative medi-
stinitis due to methicillin-resistant Staphylococcus aureus (hazard ratio, 2.13; P 
02). Treatment with antibiotics with in vitro activity against the infecting pathogen
ithin 7 days of initial debridement was associated with a decreased risk for
ortality (hazard ratio, 0.40; P  .03).
onclusions: Our data suggest that, to improve long-term survival, patients with
ostoperative mediastinitis should undergo sternal closure within 72 hours after
ternal debridement and should receive effective antimicrobial therapy based on
perative culture results.
ostoperative mediastinitis (POM) is a dreaded complication of median ster-
notomy associated with increased patient mortality and markedly increased
costs. The mortality rate among patients with POM in the immediate post-
perative period is high, with reports ranging from 11.8% to 14%, compared with
nly 2.7% to 5.5% in uninfected controls.1-3 Although the incidence of poststerno-
omy mediastinitis is low (most reports range from 0.7% to 3.4%), because median
ternotomy is a common operation, the effect of POM on individual patients and
nstitutions is great. Thus, POM continues to be an important topic of study.
Mediastinitis typically occurs approximately 2 weeks after surgery and is usually
eralded by sternal wound dehiscence or frank purulent drainage. Standard therapy
ncludes sternal debridement, sternal drainage, intensive intravenous antibiotics, and
ap closure of the mediastinum. Independent risk factors for POM have been well
hronicled and include host factors (age, obesity, diabetes, smoking status, and New
ork Heart Association functional class III or IV), variables associated with
ospitalization (prolonged mechanical ventilation, duration of stay in the inten-
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TSive care unit [ICU], and concurrent surgical-site infec-
ion), and technical factors (previous heart operation,
uration of initial operation, and need for surgical
e-exploration).1-14
A few studies have identified risk factors related to
ortality in patients with POM; in every such study, mor-
ality in the immediate postoperative period was the only
nd point analyzed. These studies concluded that the fol-
owing were risk factors for mortality in the immediate
ostoperative period: (1) variables pertaining to the host
advanced age and persistent bacteremia), (2) variables re-
ated to hospitalization (need for an intra-aortic balloon
ump, prolonged mechanical ventilation, and type of organ-
sm cultured), and (3) variables related to the operative
rocedure (prolonged duration of operation and need for
eoperation).2,15-17
Milano and colleagues3 were the first to report an in-
reased risk of long-term mortality in patients with POM,
ith the increased risk persisting for up to 2 years after
iagnosis. Since then, other groups have demonstrated that
atients with POM have a twofold to fourfold increased risk
or death anywhere from 1 to 10 years after the initial cardio-
horacic operation.3,11,18,19 Because the standard treatment for
OM necessitates surgical drainage and can result in consid-
rable morbidity, the observed increase in long-term mortality
n patients with POM compared with controls is not surpris-
ng.20 Consequently, some investigators have postulated that
OM may indeed produce long-term adverse effects on
ardiac, pulmonary, and renal function.3 Identification of
isk factors for long-term adverse outcomes in patients with
OM may potentially lead to risk-factor modification, de-
reased mortality, and improved health and functional sta-
us. The purpose of this study was to determine risk factors
or 1-year mortality in patients with POM.
aterials and Methods
tudy Design, Patient Population, and Study Setting
his was a cohort study. Patients with documented cases of po-
ential POM were prospectively identified by infection control
ractitioners using standard Centers for Disease Control defini-
ions.21 Patients with POM after coronary artery bypass grafting
CABG) and/or valve replacement at Duke University Medical
enter from 1994 to 2001 were studied. Duke University Medical
Abbreviations and Acronyms
CABG coronary artery bypass grafting
HR  hazard ratio
ICU  intensive care unit
IQR  interquartile range
MRSAmethicillin-resistant Staphylococcus aureus
POM  postoperative mediastinitisenter is a 725-bed tertiary academic medical center located in I
38 The Journal of Thoracic and Cardiovascular Surgery ● Septeurham, North Carolina. During the study period, 10,144 CABG
nd/or valve replacement operations were conducted at Duke Uni-
ersity Medical Center. Institutional review board approval was
btained for this research project.
ubject Inclusion/Exclusion Criteria
or this study, all patients with POM after CABG without a valve
peration were included. The diagnosis of POM was confirmed by
sing the Centers for Disease Control definitions for surgical-site
nfection criteria.21 Patients were required to have purulent organ-
pace infection of the mediastinum, confirmed by sternal debride-
ent. Infections of sternotomy sites that did not warrant debride-
ent clinically or that could not be confirmed by debridement
ere deemed superficial. Exclusion criteria for the study included
ge less than 18 years, patients who were heart and/or lung
ransplant recipients, patients with superficial sternal infections
nd deep infections not involving the mediastinum, patients with
uspected POM who were too ill to undergo debridement, and
atients who did not have a diagnosis of mediastinitis confirmed
y sternal debridement.
tudy Databases and Variables
ata were obtained from the Duke Infection Control Operative
atabase, the Duke cardiothoracic surgery database, and patient
harts. The following variables were prospectively recorded in the
uke Infection Control Operative Database: age, sex, procedure
ype, procedure date, National Nosocomial Infection Surveillance
isk factors (American Society of Anesthesiologists score, wound
lass, and operative duration), and the pathogen type and in vitro
ntimicrobial susceptibility pattern. The date of POM diagnosis
as defined as the date when frank purulent drainage was first
oted from the incision site. If no purulent drainage was noted
rom the incision site, then the date of diagnosis was the date of
ternal debridement when pus was drained from the mediastinum.
ata obtained from the Duke cardiothoracic surgery database were
rospectively collected and included the following: basic patient
haracteristics (weight, body-surface area, and race), comorbid
onditions before sternotomy (diabetes, congestive heart failure,
hronic obstructive pulmonary disease, hypertension, tobacco use,
nd liver disease), and the Charlson Index before sternotomy.22
nformation pertaining to hospital exposures was collected retro-
pectively by chart review and included the following: type of
urgical closure of the sternum (immediate, delayed, or healing by
econdary intention); type of surgical flap (pectoral or omental);
se of wound vacuum; admission to an ICU; use of vasopressors;
nd the need for intubation, mechanical ventilation, or both. Vital
igns (temperature, blood pressure, and heart rate) and laboratory
alues (white blood cell count, serum creatinine, and serum blood
lucose) from 24 hours before sternal debridement until 72 hours
fter debridement were also collected. Results of blood and wound
ultures along with the antibiotics used at the time of hospital
dmission for treatment of POM, on the day of sternal debride-
ent, and on days 7 and 14 after debridement were also obtained
ia chart review. The date of death was obtained from the Duke
ardiothoracic surgery database or from the Social Security Death
ndex (http://www.ssa.gov/).
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TStatistics
tatistical analysis was performed with version 8.3 of the SAS
oftware package (SAS Institute, Cary, NC). Estimates of survival
ere generated by using the Kaplan-Meier method. Dichotomous
ariables were analyzed by using Cox proportional hazards meth-
ds, and continuous and ordinal variables were analyzed by using
he Student t test and the Wilcoxon rank sum test. Hazard ratios
HRs) for 1-year mortality were determined by bivariate analysis
ith Cox proportional hazards regression methodology.
Multivariate analysis was performed with Cox proportional
azards methods. Risk factors from the bivariate analysis with a
value less than or equal to .2 and variables considered to be
mportant by the study investigators were considered for inclusion
n multivariate models. Variables to be included in the final mul-
ivariate regression model were identified by a stepwise selection
rocess. The final model was controlled for confounding covari-
tes. If a covariate changed the coefficient of a model variable by
0% or more, then the confounding covariate was retained in the
nal model. For each variable in the final multivariate model, the
roportional hazards assumption was verified by generating par-
llel log-log plots. All reported P values are two tailed, and a
value less than or equal to .05 was considered to be significant.
esults
f the 10,144 patients who underwent CABG and/or valve
eplacement operations from 1994 to 2001, 299 potential
ases of POM were prospectively identified by infection
ontrol practitioners. Of these 299 potential cases of POM,
07 cases were excluded on the basis of inclusion/exclusion
riteria, and 9 cases were excluded because the patient
harts were unavailable. The most common reason for ex-
lusion was superficial infection (n  58). Other patients
ere excluded because they had an infection at another site
s opposed to POM (n  9), because no infection was
dentified (n  11), because they were heart transplant recip-
ents (n  11), because they were too ill to undergo debride-
ent (n 5), because sternal debridement was not performed
n  3), or because of age less than 18 years (n  10).
A total of 183 cases of POM met study criteria (the inci-
ence of POM was 1.8% by study criteria; Table 1). Of these
83 patients, 139 (75.96%) initially underwent CABG, 27
14.75%) initially underwent valve operation and CABG,
0 (5.46%) underwent a revision of a prior CABG, 6
3.28%) had valve surgery only, and 1 (0.55%) underwent
ericardial stripping. The median time for diagnosis of
OM from the initial operation was 16 days (interquartile
ange [IQR], 11, 25.5 days). Sternal closure methods after
ternal debridement included flap closure (n  131;
1.58%), primary closure without a flap (n  29; 15.85%),
nd healing by secondary intention (n  23; 12.57%). Of
he 131 patients who underwent sternal flap closure, 87
66.4%) were closed by using a pectoralis major flap, and 44
33.4%) were closed by using an omental flap. The median
uration from diagnosis of POM to sternal debridement was
days (IQR, 1.4 days). Pathogens causing POM included w
The Journal of Thoracicethicillin-resistant Staphylococcus aureus (MRSA; n 
1; incidence 33%), methicillin-susceptible S aureus (n 
0; incidence 33%), and gram-negative rods (n  24; inci-
ence 13%; Table 1).
ne-Year Survival Incidence Data
urvival in the study population as a function of days after
he diagnosis of POM is shown in Figure 1. Thirty-six
atients died within the immediate 3-month postoperative
eriod (incidence of 19.6%; the median time to death was
1 days [IQR, 33.3 days] for these patients). Fifty-one
atients died within 1 year of their initial operation (1-year
ortality rate of 28%), and the median time to death was 37
ays (IQR, 11,139 days) after the diagnosis of POM (Figure 1).
ivariate Analysis of 1-Year Mortality
ivariate predictors of 1-year mortality were analyzed
Table 1). Of the host factors studied, the following were
ssociated with 1-year mortality: a Charlson score of 3 or
ore (HR, 2.55; P  .004), a history of peptic ulcer disease
HR, 3.17; P  .011), a history of congestive heart failure
HR, 2.41; P  .002), and a serum creatinine level greater
han 2.0 mg/dL before initial sternal debridement (HR, 2.62;
  .004; Table 1). Hospital-related risk factors associated
ith 1-year mortality after the diagnosis of mediastinitis
ncluded an ICU stay before the initial sternal debridement
HR, 3.66; P  .001), use of vasoactive drugs before the
nitial sternal debridement (HR, 4.793; P  .001), and the
eed for mechanical ventilation before debridement (HR,
.75; P  .001). Treatment variables associated with mor-
ality included a time from sternal debridement to sternal
losure longer than 3 days (compared with patients who
nderwent sternal closure in 3 days or shorter; HR, 2.38;
  .027; Figure 2) and no flap performed after sternal
ebridement (HR, 3.65; P  .008). In terms of pathogens,
OM due to MRSA was significantly associated with 1-year
ostoperative mortality compared with POM due to other
athogens (HR, 2.65; P  .001).
ultivariate Analysis of 1-Year Mortality
ndependent predictors of 1-year mortality among patients
ith POM included age older than 65 years (HR, 2.29; P 
015); serum creatinine level greater than 2.0 mg/dL before
ternal debridement (HR, 2.52; P  .019); stay in an ICU
efore initial sternal debridement (HR, 5.56; P  .001);
OM due to MRSA (HR, 2.13; P .019); a delay in sternal
losure after sternal debridement of more than 3 days (com-
ared with patients who underwent closure in3 days; HR,
.27; P  .001); and not receiving flap closure after sternal
ebridement (HR, 7.70; P  .002; Table 2). Treatment with
ntibiotics with in vitro activity against the infecting patho-
en within 7 days after initial debridement was associated
ith a decreased risk for mortality (HR, 0.40; P  .030).
and Cardiovascular Surgery ● Volume 132, Number 3 539
TV
D
C
H
O
S
I
T
M
General Thoracic Surgery Karra et al
5
G
TSABLE 1. Bivariate predictors of 1-year mortality
ariable Alive at 1 y (n  132) Dead at 1 y (n  51)
Hazard ratio
(95% confidence interval) P value
emographic data
Age, y (mean SD) 63.64 9.92 66.53 8.06 NA .06
Age 65 y 73 (55.30%) 35 (68.63%) 1.69 (0.93, 3.05) .08
Female sex 53 (40.15%) 19 (37.25%) 0.89 (0.50-1.56) .67
White race 82 (62.12%) 33 (64.71%) 1.05 (0.59 -1.86) .87
BMI, kg/m2 (mean  SD) 30.27 6.49 29.49 6.72 0.99 (0.94-1.03) .50
omorbid conditions
Obesity (BMI 30 kg/m2) 59 (44.70%) 20 (40.00%) 0.85 (0.48-1.50) .58
CHF present before initial operation 45 (34.35%) 30 (60.00%) 2.412 (1.37-4.25) .002
History of MI 53 (40.15%) 21 (42%) 1.08 (0.61-1.89) .79
History of PVD 27 (20.45%) 10 (20.00%) 0.954 (0.48-1.91) .89
History of CVA 13 (9.85%) 14 (28.00%) 2.78 (1.49-5.18) .001
History of hypertension 92 (69.70%) 38 (76.00%) 1.35 (0.70-2.58) .37
Preoperative blood glucose 200 mg/dL 19 (14.62%) 9 (17.65%) 1.23 (0.60-2.53) .58
History of diabetes 62 (46.97%) 27 (54.00%) 1.23 (0.71-2.15) .47
History of tobacco use 85 (64.39%) 27 (54.00%) 0.68 (0.39-1.19) .17
History of COPD 17 (12.88%) 6 (12.00%) 0.97 (0.41-2.28) .94
History of PUD 5 (5.26%) 6 (18.18%) 3.17 (1.30-7.75) .01
History of renal disease 9 (9.78%)
(n  92)
8 (25.00%)
(n  32)
2.43 (1.09-5.45) .03
Preoperative serum Cr 2 mg/dL 12 (6.56%) 12 (6.56%) 2.62 (1.37-5.02) .004
Charlson (mean SD) 1.11  1.13 1.49 1.19 1.22 (0.99-1.50) .06
Charlson 2 13 (9.85%) 13 (25.49%) 2.55 (1.35-4.81) .004
ospital risk factors
In ICU 24 h before initial debridement 19 (14.73%) 23 (46.94%) 3.66 (2.08-6.43) .001
On pressors before initial debridement 6 (4.65%) 13 (26.53%) 4.79 (2.52-9.09) .001
Intubated before initial debridement 6 (4.65%) 11 (22.00%) 3.75 (1.91-7.39) .001
perative variables at initial operation
Need for urgent operation 47 (35.61%) 16 (31.37%) 0.87 (0.48-1.56) .63
ASA* III before surgery 115 (87.12%) 51 (100%) 3960465 (0.00-not defined) .98
urgical-site infection variables
Time from initial operation to POM
diagnosis, d (mean SD)
25.69 34.37 20.57 14.49 0.99 (0.98-1.01) .34
Time to debridement from diagnosis of
POM, d (mean SD)
5.27 25.54 3.31 3.95 0.99 (0.97-1.02) .65
Time from POM diagnosis to sternal
closure, d (mean SD)
5.41 4.03
(n  118)
7.5  6.13
(n  42)
1.07 (1.02-1.12) .01
nfecting organism
MRSA† 34 (25.76%) 27 (52.9%) 2.65 (1.35-5.18) .001
MSSA† 50 (37.88%) 12 (23.53%) 0.96 (0.43-2.10) .07
ime from diagnosis of mediastinitis to
sternal closure with a flap‡
3 d 47 (35.61%) 8 (15.69%) — —
3 d 71 (53.79%) 34 (66.67%) 2.38 (1.10-5.16) .03
No flap 14 (10.61%) 9 (17.65%) 3.65 (1.40-9.49) .01
ethod of closure
Primary closure 24 (18.18%) 5 (9.80%) 0.55 (0.22-1.38) .20
Secondary intention 14 (10.6%) 5 (9.80%) 1.00 (0.40-2.52) 1.00
Flap of any type 94 (71.21%) 37 (72.55%) 0.96 (0.52-1.77) .88
Pectoralis flap 64 (48.4%) 23 (45.10%) 0.83 (0.48-1.44) .51
Omental flap 30 (22.73%) 14 (27.45%) 1.22 (0.66-2.25) .53
Use of a WoundVac 27 (20.45%) 7 (13.73%) 0.69 (0.31-1.52) .35
40 The Journal of Thoracic and Cardiovascular Surgery ● September 2006
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TShe final multivariate model was controlled for the presence
r absence of heart failure.
iscussion
his was the first study, to our knowledge, that analyzed
isk factors for 1-year mortality after POM. In addition to
dentifying risk factors previously reported as predictors of
ortality in the immediate postoperative period (such as age
nd type of infecting organism), we also identified risk
actors for mortality not previously identified, including the
ack of flap closure, the time to flap closure after sternal
ebridement, treatment with antibiotics effective against the
nfecting organism within 7 days of debridement, renal
ailure, and ICU stay before surgery.2,15-17
We found that a greater than 3-day delay between sternal
ebridement and sternal closure was the strongest indepen-
ent predictor of 1-year mortality in patients with POM,
ncreasing the risk for mortality more than sixfold. Patients
ith delayed sternal closure likely represented two diverse
opulations: the first, patients with severe infection and/or
emodynamic instability, clinical features that may have
Figure 1. Survival after diagnosis of postoperative mediastinit
(POM). The probability of survival is plotted as a function of da
ABLE 1. Continued
ariable Alive at 1 y (n 
ntibiotic treatment
Treatment with antibiotics effective against
isolate within 7 d after debridement
117 (90.70%
Treatment with antibiotics effective against
isolate at time of POM diagnosis
110 (85.27%
A, Not applicable; BMI, body mass index; CHF, congestive heart failure;M
ccident; COPD, chronic obstructive pulmonary disease; PUD, peptic ulcer
f Anesthesiologists; POM, postoperative mediastinitis; MRSA, methicillin-r
ureus. *American Society of Anesthesiologists physical status grouping
azard ratios are with reference to the group with the time to flap less thafter the initial diagnosis of POM. r
The Journal of Thoracicrevented prompt sternal closure; and the second, hemody-
amically stable patients who had delays in sternal closure
ossibly due to competing issues or scheduling difficulties.
o address potential bias between delayed sternal closure
nd an increased severity of illness or hemodynamic insta-
ility, the final multivariate model was adjusted for indices
f baseline health and acute illness. After adjustment for
everity of illness, the association between delayed sternal
losure and mortality persisted. Although this finding will
eed to be verified in subsequent data sets, on the basis of
he current study results, every effort should be made to
lose the sternum within 3 days of sternal debridement.
Furthermore, patients who received antibiotics active
gainst the infecting pathogen within 7 days of sternal
ebridement had a significantly decreased risk for mortality.
his finding underscores the importance of using antibiotics
ith a spectrum of activity to include MRSA, obtaining
eep cultures during sternal debridement, verifying culture
igure 2. Survival after the diagnosis of postoperative mediasti-
itis (POM) and the time to flap closure. Survival in days after the
iagnosis of POM is plotted for the group receiving no flap, the
roup receiving a flap within 3 days of diagnosis, and the group
) Dead at 1 y (n  51)
Hazard ratio
(95% confidence interval) P value
37 (82.22%) 0.54 (0.25-1.17) .12
41 (83.67%) 0.88 (0.41-1.89) .75
cardial infarction; PVD, peripheral vascular disease; CVA, cerebrovascular
se; Cr, serum creatinine; ICU, intensive care unit; ASA, American Society
nt Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus
erence group is organisms other than MRSA and MSSA. ‡P values and
days.is
ys132
)
)
I, myo
disea
esista
. †Refeceiving a flap more than 3 days after diagnosis.
and Cardiovascular Surgery ● Volume 132, Number 3 541
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TSesults, and modifying therapy promptly according to in
itro susceptibility results. Other therapeutic interventions
including the type of mediastinal flap and use of a Wound-
ac) were not significantly associated with 1-year mortal-
ty. Increased age, renal failure before CABG, and ICU
dmission before sternal debridement were also associated
ith increased mortality and likely represent markers for
atients with increased acute illness and chronic comorbid
onditions that predispose to severe POM and death. Pa-
ients with these risk factors may require specific interven-
ions to prevent POM, perhaps by maintaining health status
hrough adequate hydration and minimizing the use of neph-
otoxic agents during the perioperative and postoperative
eriods.
Our results provide some insight into the epidemiology
nd pathophysiology of POM. Although S aureus has been
ell documented as the most common pathogen isolated in
atients with POM, we identified MRSA in particular as the
athogen most strongly associated with mortality.2 This
nding is consistent with previous work by our group that
eported a greater than 3-fold increase in 90-day postoper-
tive mortality in patients with surgical-site infection due to
RSA compared with surgical-site infection due to
ethicillin-susceptible S aureus and an 11-fold increase in
ortality compared with uninfected surgical patients.23-25
OM due to MRSA might represent a particularly refractory
ype of POM, because antibiotic options are limited and
uboptimal. Because standard perioperative antimicrobial pro-
hylaxis regimens do not provide coverage against MRSA,
ltering perioperative surgical prophylaxis regimens that pro-
ide coverage against MRSA and/or using mupirocin before
urgery to reduce rates of colonization with MRSA might
revent some cases of POM due to MRSA and thus second-
rily reduce POM-related mortality.26-28
This study had limitations. Although the study represents
ne of the largest cohorts of patients with documented
OM, statistical power was limited when subgroups were
nalyzed. For example, small sample sizes precluded inten-
ABLE 2. Multivariate predictors of 1-year mortality*
ariable
ge 65 y
erum creatinine 2.0 mg/dL the day before initial operation
n ICU within 24 h before debridement
RSA†
ime from sternal debridement to flap closure of sternum 3 d‡
o flap after diagnosis‡
ffective antibiotic treatment within 7 d after initial debridement
CU, Intensive care unit; MRSA, methicillin-resistant Staphylococcus aureu
ther than methicillin-resistant Staphylococcus aureus or methicillin-susce
3 days from diagnosis of mediastinitis.ive analysis of patients who underwent different methods
42 The Journal of Thoracic and Cardiovascular Surgery ● Septef mediastinal flap closure. Another limitation is that the
tudy results come from a single institution and might not be
eneralizable to other hospitals. Finally, although cases
ere identified prospectively, detailed data were abstracted
rom patient charts retrospectively, thus potentially intro-
ucing bias into the study. However, we used detailed
rotocols to obtain data and reviewed these protocols care-
ully with study personnel, thus limiting the extent of bias.
ecause of the observational nature of the study, we cannot
ule out the presence of other possible confounding vari-
bles that might have affected study results.
In summary, our work has identified risk factors for
-year mortality in patients with POM. When patients with
OM initially present, they should undergo adequate de-
ridement and sternal closure in less than 72 hours after
ternal debridement and should receive effective definitive
ntimicrobial therapy based on operative culture results.
ur findings illustrate the clinical importance of selecting
reoperative surgical antimicrobial prophylaxis to cover
athogens that are known or expected to cause POM. The
est way to do this is for hospitals to monitor and trend their
ates of POM and analyze the pathogens that commonly
ause postoperative infections in their institutions. Indeed,
e believe that it is notable and important that in this study,
RSA caused approximately one third of cases of POM at
ur hospital. This in turn has prompted us to develop preop-
rative strategies to identify patients who are likely to be
olonized with MRSA. These patients then receive antimicro-
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